Publications Database

Aman M. G. et al. (2014)

A review of atomoxetine effects in young people with developmental disabilities.

Research in Developmental Disabilities

June, 35(6), pp. 1412-1424.

Read Full (New Window)

Aman M. G. et al. (2005)

Acute and long-term safety and tolerability of risperidone in children with autism.

Journal of Child and Adolescent Psychopharmacology

15(6), pp. 869-884

Read Abstract (New Window)

Aman M. G. et al. (2008)

Cognitive effects of risperidone in children with autism and irritable behavior.

Journal of Child and Adolescent Psychopharmacology

18(3), pp. 227-236

Read Abstract (New Window) Read Full (New Window)

Aman M. G. et al. (2009)

Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial.

Journal of the American Academy of Child and Adolescent Psychiatry

48(12), pp. 1143-1154

Read Abstract (New Window) Read Full (New Window)

Aman M. G. et al. (2015)

Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial.

Journal of Child and Adolescent Psychopharmacology

August, 25(6), pp. 482-493.

Read Abstract (New Window) Read Full (New Window)

Aman M. G. , Hollway J. A. , Arnold L. E. (2008)

Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.

Child and Adolescent Psychiatric Clinics of North America

17(4), pp. 713-738

Read Abstract (New Window)

Anagnostou E. et al.

Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: A randomized clinical trial.

JAMA Psychiatry

Read Abstract (New Window)

Anderson G. M. et al. (2007)

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.

February, 61(4), pp. 545-550.

Read Abstract (New Window)

Arnold L. E. et al.

A 1.5-year follow-up of parent training and atomoxetine for attention-deficit hyperactivity disorder symptoms and noncompliant-disruptive behavior in autism.

Journal of Child and Adolescent Psychopharmacology

Read Abstract (New Window)

Arnold L. E. et al. (2000)

Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network.

Journal of Autism and Developmental Disorders

April, 30(2), pp. 99–111

Read Abstract (New Window)

Arnold L. E. et al. (2006)

Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.

Journal of the American Academy of Child and Adolescent Psychiatry

45(10), pp. 1196-1205

Read Abstract (New Window)

Arnold L. E. et al. (2003)

Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials.

Journal of the American Academy of Child and Adolescent Psychiatry

42(12), pp. 1443-1450

Read Abstract (New Window)

Arnold L. E. et al. (2012)

Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.

Journal of Child and Adolescent Psychopharmacology

22(3), pp. 198-205.

Read Abstract (New Window)

Arnold L. E. et al. (2012)

Research Units of Pediatric Psychopharmacology (RUPP) Autism Network randomized clinical trial of parent training and medication: One-year follow-up.

Journal of the American Academy of Child and Adolescent Psychiatry

51(11), pp. 1173-1184.

Read Abstract (New Window) Read Full (New Window)

Carroll D. et al. (2014)

Examination of aggression and self injury in children with autism spectrum disorders and serious behavioral problems.

Child and Adolescent Psychiatric Clinics of North America

January, 23(1), pp. 57-72.

Read Abstract (New Window)

Farmer C. A. et al. (2012)

Predictors and moderators of parent training efficacy in a sample of children with autism spectrum disorders and serious behavioral problems.

Journal of Autism and Developmental Disorders

June, 4(6), pp. 1037-1044.

Read Abstract (New Window)

Handen B. L. et al. (2015)

Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention deficit hyperactivity disorder.

Journal of the American Academy of Child and Adolescent Psychiatry

November, 54(11), pp. 905-915.

Read Abstract (New Window)

Hellings J. A. , Arnold L. E. , Han J. C. (2017)

Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline.

Experimental and Clinical Psychopharmacology

18(6), pp. 581-588.

Read Abstract (New Window)

Jahromi L. B. et al. (2009)

Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity.

Journal of Autism and Developmental Disorders

39(3), pp. 395-404

Read Abstract (New Window)

Lecavalier L. et al.

Parent stress in a randomized clinical trial of atomoxetine and parent training for children with autism spectrum disorder.

Journal of Autism and Developmental Disorders

Read Abstract (New Window)